Maegim

Stock search

Search by company name, 6-digit code, or Korean initials (e.g. ㅅㅅㅈㅈ)

☆한국어

UNION KOREA PHARM CO.,Ltd

한국유니온제약080720KOSDAQSector: Pharma & Biotech
₩2,4100.00%Market cap ₩47.8BAs of Sep 2, 2026 close · updated once daily
Market cap
₩47.8B
#1154 in KOSDAQ
Loss
PER not computable
Impaired equity
PBR not computable
0.0%
Sector median 0.0%
Trading halted — grade display suspended

This stock is under a trading halt per KRX disclosure. Grade display resumes once trading resumes.

See withholding criteria →View source filing (DART) ↗

This grade is not a buy/sell recommendation — it is information mechanically scored from public data using a fixed formula.

1-year closing price

Loading closing price history…
 
Low ₩2,410High ₩2,410
Latest close
Price change by period
1W
0.00%
1M
0.00%
3M
0.00%
1Y
0.00%

Adjusted for 1 price-basis change(s) such as stock splits or reverse splits during the period.

As of the Sep 2, 2026 close · updated once daily · a factual record computed from closing prices only; dividends are not included, and this is not a buy or sell signal.

1

Financial strength

9.4/100
How much debt does it carry relative to equity?
Negative equity (not computable)
Sector median 51.6%
Sector lowhighBottom 0.6% in sector
Can it cover what's due within a year?
33.7%
Sector median 191.7%
Sector lowhighBottom 2.6% in sector
How much of revenue becomes profit?
-47.4%
Sector median -2.4%
Sector lowhighBottom 33.8% in sector
How much did it earn on its own capital?
Negative equity (not computable)
Sector median -4.5%
Sector lowhighBottom 0.6% in sector

Source filing: annual report (consolidated) — view original ↗

2

Growth momentum

11.6/100
How much did revenue grow in a year?
-29.1%
Sector median 6.4%
Sector lowhighBottom 8.4% in sector
Has it grown steadily over three years?
-16.0%
Sector median 4.9%
Sector lowhighBottom 11.8% in sector
Did core profits grow in a year?
-28.1%
Sector median 3.6%
Sector lowhighBottom 24.2% in sector
Are core profits higher than three years ago?
-1455.3%
Sector median 3.5%
Sector lowhighBottom 1.9% in sector

Financial trend

Revenue

Growth & margin

Revenue growth Operating margin

Year over year — alongside the sector median

This stock Sector median

A factual chart of confirmed annual results from annual reports — the same source as the grading indicators. Not a buy or sell signal.

Source filing: annual report (consolidated) — view original ↗

3

Price attractiveness

2.7/100
Is the price expensive relative to earnings?
Loss-making (P/E not computable)
Sector median P/E of profitable peers 16.3x · 58% loss-making
Sector lowhighBottom 5.1% in sector
Is the price expensive relative to book value?
Negative equity (not computable)
Sector median 1.61x
Sector lowhighBottom 0.2% in sector

Valuation uses the Sep 2, 2026 close and market cap

4

Shareholder Return

Single-indicator axis37.5/100
Does the company actually pay dividends?
0.0%
Sector median 0.0%
Sector lowhighBottom 37.5% in sector

Dividends & treasury shares

Treasury shares (FY2025)
683,333 shares (8.6% of shares issued)

Source: annual report (DART) — dividend allocation & total shares

Source filing: annual report (consolidated) — view original ↗

Financial checklist

Based on the FY2025 annual report · year-over-year comparison · determined on Sep 2, 2026

Of 9 items: 2 met · 7 not met · 0 not computable

Not metMetNot computable

Positive net income
Whether net income (attributable to owners where available) is above zero.
Not met
-₩30.8B
Positive operating cash flow
Whether cash flow from operations is above zero.
Not met
-₩1.1B
Return on assets up
Whether net income over beginning total assets rose from the prior year.
Not met
-22.1% → -41.1%
Operating cash flow exceeds net income
Whether operating cash flow is greater than net income.
Met
-₩1.1B vs -₩30.8B
Liabilities-to-assets ratio down
Whether total liabilities as a share of total assets fell from the prior year.
Not met
89.0% → 150.0%
Current ratio up
Whether current assets over current liabilities rose from the prior year.
Not met
62.9% → 33.7%
Shares outstanding not increased
Whether common shares issued did not increase from the prior year. Increases from bonus issues and stock dividends are also counted.
Met
7,912,828 → 7,912,828
Operating margin up
Whether operating income over revenue rose from the prior year.
Not met
-26.2% → -47.4%
Asset turnover up
Whether revenue over beginning total assets rose from the prior year.
Not met
0.54x → 0.49x

A record of facts determined by fixed rules from the financial statements in the latest annual report. Not used in grading, and not a buy or sell signal. Source filing: annual report (consolidated) — view original ↗

Grade change history

Jul 23, 2026F

Methodology version change (v2.0 applied)

Jul 15, 2026FVersion v1

First calculation

Grade changes are a factual record produced from public data by a fixed formula; they do not signal future changes.

Disclosure & financial badges

Factual records determined from public filings and periodic reports by fixed rules — not buy/sell signals.

Negative-evidence group (dilution, loss, dispute)Mixed interpretationPositive-evidence group (shareholder return)Dots classify the disclosure type by the direction of research evidence — not an assessment or investment judgment about this company.

Disclosure event history

Large paid-in capital increase resolved

Disclosed a paid-in capital increase (제3자배정증자) issuing 60,000,000 new shares, equal to 302.2% of shares outstanding before the increase (filed 2026-08-19). 2 filings meeting the same criteria were disclosed in the past 24 months. View filing ↗

Private CB/BW issuance resolutions (past 36 months)

2 private-placement convertible bond (CB) / bond-with-warrants (BW) issuance resolutions were disclosed in the past 36 months (latest filing 2025-01-24). View filing ↗

CB with conversion-price adjustment clause (past 36 months)

1 convertible bond (CB) issuance resolutions including a downward conversion-price adjustment (refixing) clause were disclosed in the past 36 months (latest filing 2024-05-13). View filing ↗

CEO (representative executive officer) change filings (past 36 months)

4 CEO (representative executive officer) change filings were submitted in the past 36 months (latest filing 2026-07-21). View filing ↗

Financial fact combinations

Operating losses for 3 consecutive fiscal years

Recorded operating losses in three consecutive fiscal years, FY2023–FY2025 (per annual reports).

Determined as of 2026-09-02

Recent filings for this stock

Last 120 days · monitored filing types only
Paid-in capital increaseAug 19, 2026Source ↗
Periodic report filedAug 14, 2026Source ↗
Capital reductionAug 11, 2026Source ↗
Paid-in capital increaseAug 11, 2026Source ↗
CEO changeJul 21, 2026Source ↗

View in the filings calendar →